Erdinç Nayır, Associate Professor of Internal Medicine and Medical Oncology at VM Medicalpark Mersin Hospital, shared a post on X:
“The FDA has approved TTFields in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.
Phase 3 PANOVA-3: n≈570 Gemcitabine + nab-paclitaxel ± TTFields Median OS: 16.2 vs 14.2 months HR ≈0.82 No increase in systemic toxicity.
Most common AE: localized dermatitis. Not a replacement for chemotherapy, but a combinational modality with modest yet meaningful survival benefit.”
PANOVA-3 Leads to FDA Approval of Optune Pax in Locally Advanced Pancreatic Cancer